Urologytimes.com reports that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of pembrolizumab (Keytruda) for the adjuvant treatment of adults with renal cell carcinoma (RCC) at increased risk of...
Pembrolizumab (Keytruda) is a type of immunotherapy. It stimulates the body’s immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find...
The Scottish Medical Consortium have recommended Pembrolizumab (Keytruda) as a monotherapy which is indicated for the adjuvant treatment of adults with RCC with increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic...
Data from the LITESPARK-022 study supported adding belzutifan (Welireg) to standard adjuvant pembrolizumab for patients with clear cell renal cell carcinoma (RCC) that has a high chance of recurring following nephrectomy according to a report in MedScape.com. In this...
Recently published in the New England Journal of Medicine, findings from the pivotal phase 3 trial, KEYNOTE-564, underscore a crucial development in adjuvant therapy for patients diagnosed with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence. Led...
There are many terms associated with kidney cancer. Kidney Cancer UK has collated a comprehensive glossary of terms to help patients, carers and health professionals find the information they need.
Kidney Cancer Vaccine Shows Promise in Early Trial The vaccine generated robust immune response in nine patients with advanced disease All patients remained cancer-free for an average of 3 years. The findings remain to be replicated in larger studies. In a small...
Kidney Cancer UK have collated information about the current drug based treatment options.
There are many questions that kidney cancer patients and their families may have. Kidney Cancer UK have collated a list of the most frequently asked questions and their answers.
Well, I’ve been on a ride, that’s for sure! It all started for me at Christmas 2020, when as a man of a particular age, 53, who loves cycling, I developed what I thought was prostatitis. So, I stayed off the bike for a while and after six weeks the bike, it was not...
Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), the most common form of kidney cancer writes pharmaphorum.com The disappointing...
Axitinib is a tyrosine kinase inhibitor (TKI) which is a cancer growth blocker. Tyrosine kinase inhibitors work by blocking certain proteins called tyrosine kinases from acting on cells. Tyrosine kinases signal to cancer cells to grow. Axitinib blocks different types...
Lenvatinib as a single agent and is available in the whole of the UK. Lenvatinib is indicated 'in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted...
The drug duo Kisplyx plus Keytruda led to improved outcomes for patients with advanced renal cell carcinoma, extended follow-up of the CLEAR trial showed. Kisplyx (lenvatinib) plus Keytruda (pembrolizumab) improved outcomes in patients with advanced renal cell...
I’m Kevin. I’m 67, and I never imagined my life would change so suddenly, or so dramatically. My cancer journey began with symptoms that were impossible to ignore. Persistent night sweats, then sudden, severe pain on the right side of my abdomen, followed by a...
Cancer treatments can affect your mouth and dental health, so it is important to get a dental check-up before starting therapy. Cancer treatments for kidney cancer can affect the mouth, teeth, gums, throat, and salivary glands. These changes can be uncomfortable and,...
